gip/glp-1 The activity of GLP-1 and GIP for Type 2 Diabetes and Obesity Beyond the pancreas: contrasting cardiometabolic

The ACHIEVE-3 head-to-head trial showed slightly higher discontinuation with orforglipron than with oral semaglutide, consistent with orforglipron's greater potency and attendant greater GI activation

Compounded drugs can be important for overcoming shortages or meeting unique patient needs but compounders should not try to compound drugs in a way that circumvents FDAs approval process. The 30 companies that received warning letters are mostly small to midsize, digital telehealth providers that moved quickly to meet surging consumer demand for GLP-1 weight loss therapies when manufacturing capacity constraints limited supplies

To view or add a comment, sign in Keenova eyes Xiaflex as first drug for plantar fibromatosis: Ireland's Keenova is hoping that its Xiaflex therapy can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet

Like AA, Rossini AA

The most common adverse effects associated with GLP-1 medications are gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort